Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial

Intensive Care Medicine

Volumn 44, Issue 12, 2018, Pages 2205-2212

  Klein, D J ^a   Foster, D ^b   Walker, P M ^b   Bagshaw, S M ^c   Mekonnen, H ^d   Antonelli, M ^e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Spectral Diagnostics Inc   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d Amarex Clinical Research   (United States)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

Endotoxemia; Endotoxin; Hemoperfusion; Polymyxin B; Precision medicine; Sepsis; Septic shock

Indexed keywords

CORTICOSTEROID; HEPARIN; HYPERTENSIVE FACTOR; NORADRENALIN; POLYMYXIN B; ANTIINFECTIVE AGENT;

ADULT; ANEMIA; APACHE; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; DEEP VEIN THROMBOSIS; DIALYSIS; EMBOLISM; ENDOTOXEMIA; FEMALE; HEMOPERFUSION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; MORTALITY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; SURVIVAL TIME; VEIN EMBOLISM; AGED; ARTERIAL PRESSURE; COMPLICATION; CONTROLLED STUDY; INTENSIVE CARE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ARTERIAL PRESSURE; CRITICAL CARE; ENDOTOXEMIA; FEMALE; HEMOPERFUSION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; POLYMYXIN B; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 85057133037     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-018-5463-7     Document Type: Article

References (27)

1. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE (1991) Endotoxemia in human septic shock. Chest 99(1):169–175
2. Angus DC, Birmingham MC, Balk RA et al (2000) E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 283(13):1723–1730
3. Dellinger RP, Tomayko JF, Angus DC et al (2009) Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 37(11):2929–2938
4. Levin M, Quint PA, Goldstein B et al (2000) Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356(9234):961–967
5. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121(1):1–5
6. Opal SM, Laterre PF, Francois B et al (2013) Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309(11):1154–1162
7. Marshall JC, Foster D, Vincent JL et al (2004) Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 190(3):527–534
8. Shoji H (2003) Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 7(1):108–114. 10.1046/j.1526-0968.2003.00005.x
9. Ronco C, Klein DJ (2014) Polymyxin B hemoperfusion: a mechanistic perspective. Crit Care 9;18(3):309
10. Cruz DN, Antonelli M, Fumagalli R et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301(23):2445–2452
11. Payen DM, Guilhot J, Launey Y et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41(6):975–984
12. Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP (2014) The EUPHRATES trial (Evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock): study protocol for a randomized controlled trial. Trials 15:218. 10.1186/1745-6215-15-218
13. Dellinger RP, Bagshaw SM, Antonelli M et al (2018) Targeted Polymyxin-B hemoperfusion for the treatment of endotoxemia and septic shock: a multicenter randomized controlled trial (EUPHRATES). JAMA 20(14):1455–1463. 10.1001/jama.2018.14618
14. Pocock Stuart J, Stone Gregg W (2016) The primary outcome fails—now what? N Engl J Med 375:861–870. 10.1056/NEJMra1510064
15. Romaschin AD, Obiezu-Forster CV, Shoji H, Klein DJ (2017) Novel insights into the direct removal of endotoxin by polymyxin B hemoperfusion. Blood Purif 44(3):193–197
16. Dünser MW, Ruokonen E, Pettilä V, Ulmer H, Torgersen C, Schmittinger CA, Jakob S, Takala J (2009) Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 13(6):R181
17. Standford Lab—Lab Test Guide. https://www.stanfordlab.com/LabTestGuide/. Accessed 01 May 2018
18. Moya-Horno I, Viteri S, Karachaliou N, Rosell R (2018) Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). Ther Adv Med Oncol. 10.1177/1758834017745012
19. Reck M, Rabe KF (2017) Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med 377:849–861
20. Ferretti G, Ruberto F, Morabito V, Pugliese F (2010) Early management of endotoxemia using the endotoxin activity assay and polymyxin B-based hemoperfusion. Contrib Nephrol 167:91–101
21. Cutuli SL, Artigas A, Fumagalli R et al (2016) Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care 6(1):77
22. Iwagami M, Yasunaga H, Noiri E, Horiguchi H, Fushimi K, Matsubara T, Yahagi N, Doi K (2016) Potential survival benefit of polymyxin B hemoperfusion in spetic shock patients on continuous renal replacement therapy: a propensity-matched analysis. Blood purif 42:9-17
23. Zhou F, Peng Z, Murugan R, Kellum JA (2013) Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 41(9):2209–2220
24. Chang T, Tu YK, Lee CT, Chao A, Huang CH, Wang MJ, Yeh YC (2017) Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med 45(8):e858–e864
25. Venkatesh B, Finfer S, Cohen J et al (2018) Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 378:797–808. 10.1056/NEJMoa1705835
26. Suffredini AF (2018) A role for hydrocortisone therapy in septic shock? N Engl J Med 378:860–861
27. Srisawat N, Tungsanga S, Lumlertgul N et al (2018) The effect of polymyxin B hemoperfusion on modulation on human leukocyte antigen DR in severe sepsis patients. Crit Care 22:279. 10.1186/s3054-018-2077-y